Science 1st - Designing Nucleic Acid Medicines
JLABS , 3210 Merryfield Row , San Diego , CA 92121
September 13, 2017 from 17:00 PM to 21:00 PM (PST)
$10 - $35
We are closer than ever to realizing the promise of medicines that address a diversity of human maladies by supporting, supplanting, or suppressing the genetic expression patterns within patient's cells. Whether the goal is to provide new genetic expression to the cell or to modulate existing expression, we must learn how to dose these new medicines to provide meaningful therapeutic indexes. To achieve that, we must understand the fundamental control mechanisms of gene expression exercised through a diversity of players including RNAs, DNA domains, and proteins that act upon chromatin or transcripts.
Johnson & Johnson Innovation, JLABS (JLABS) is bringing together leading San Diego scientific experts to share their data and insights advancing our understanding in this fascinating and complex space.
- Control of RNA expression and translation
- RNA Editing
- Pre-clinical modeling of nucleic acid medicines
- Vectors and Delivery to Patients
3:00pm | Registration and networking
3:25pm | Introduction
3:30pm | Presentation and Q&A
4:30pm | Panel Discussion and Q&A
5:30pm | Networking Reception
7:00pm | Program Close
Gene W. Yeo, Ph.D. | Professor of Cellular and Molecular Medicine, UCSD read bio»
Christine Esau | Director of Translational Biology, Arcturus Therapeutics read bio»
[moderator] Beth Hill | Senior Director, Platform Innovation, Johnson & Johnson Innovation read bio»
Tu Diep | VP of Operations, OncoSec read bio»
$25 | General Public
$15 | Student/Academic
$35 | At the door
3210 Merryfield Row
San Diego, CA
About the Science First series:
The Science First series, sponsored by Johnson & Johnson Innovation, JLABS, brings together top experts to explore pressing topics in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.
Gene W. Yeo, Ph.D. | Professor of Cellular and Molecular Medicine, UCSD
Dr. Gene Yeo is an expert in the areas of RNA, computational biology, genomics and neurological diseases. Dr. Yeo obtained a bachelor of science in chemical engineering and a bachelor of arts in economics from the University of Illinois, Urbana-Champaign (1998) and a master’s degree in business administration from the Rady School of Management at the University of California, San Diego (2008). Funded by the Lee Kuan Yew Graduate Fellowship from Singapore, Dr. Yeo earned a Ph.D. in Computational Neuroscience (2005) from the Massachusetts Institute of Technology under the joint guidance of Dr. Tomaso Poggio and Dr. Christopher Burge. Using comparative genomics and statistical learning theory Dr. Yeo pioneered new computational approaches to attack the problem of splicing and splicing-mediated gene regulation.
Christine Esau | Director of Translational Biology, Arcturus Therapeutics
Dr. Esau has more than fifteen years of experience in oligonucleotide drug discovery. At Isis Pharmaceuticals and Regulus Therapeutics, she performed pioneering work in microRNA targeting and biology, moving several programs from discovery biology to lead candidate selection. Dr. Esau also served as Chief Scientific Officer of AptamiR Therapeutics, developing a microRNA based therapy for the treatment of obesity. Currently at Arcturus she oversees siRNA and mRNA therapeutics programs for the treatment of hepatitis B virus and orphan genetic diseases such as OTC deficiency and cystic fibrosis. Dr. Esau earned a B.S. degree in biology from the California Institute of Technology and a Ph.D. from the Massachusetts Institute of Technology.
Tu Diep | VP of Operations, OncoSec
Tu Diep has more than 10 years of experience in scientific and clinical research. Prior to joining OncoSec, Mr. Diep was at Protox Therapeutics Inc., (now Sophiris Bio Inc.), a company developing highly targeted, minimally invasive treatment for benign prostatic hyperplasia. During Mr. Diep’s 6 years at Protox, he held a number of positions of increasing responsibility where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing. Prior to leaving Protox, he was integrally involved in solidifying a $75 million regional partnership with the Japanese pharmaceutical company Kissei, as well as, securing a $35 million investment from the private equity firm, Warburg Pincus. At OncoSec, Mr. Diep has held positions of increasing responsibility including Executive Director, Clinical Development, where he led the clinical research and operations for the Company. As VP of Operations, he oversees day-to-day operations and also leads the business development efforts at OncoSec. Mr. Diep holds a Master of Science in Physiology from the University of Toronto.
[moderator] Beth Hill, Ph.D. | Senior Director, Platform Innovation, Johnson & Johnson Innovation
Beth Hill is Senior Director of Platform Innovation at Johnson & Johnson Innovation, California. She is an experienced pharmaceutical innovator with many years of strategic and operational leadership in creating and applying technologies that overcome technical and business barriers. Formerly with Janssen R&D, Beth led global cross-disciplinary functions working from late discovery through development and commercialization with a focus on drug delivery and drug+device combination products. Beth has also led R&D teams to develop therapeutics for cancer and autoimmune disease. At Systemix /Novartis she held functional and project leadership roles in stem, somatic cell and gene therapies. She began her industrial career developing antibody-based diagnostics at Syva Co. Beth earned her BA in Medical Technology at Augustana College, her PhD in Microbiology at Columbia University, and completed her post-doctoral studies in the Stanford Department of Structural Biology.
Connect with Beth: